Agenus (NASDAQ:AGEN – Get Free Report)‘s stock had its “neutral” rating restated by HC Wainwright in a note issued to investors on Wednesday,Benzinga reports.
Agenus Stock Performance
Shares of AGEN opened at $1.68 on Wednesday. The firm has a market cap of $39.29 million, a P/E ratio of -0.15 and a beta of 1.23. Agenus has a twelve month low of $1.67 and a twelve month high of $19.69. The firm’s 50 day moving average price is $3.23 and its two-hundred day moving average price is $3.84.
Agenus (NASDAQ:AGEN – Get Free Report) last announced its earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.36) by $0.32. The company had revenue of $26.84 million during the quarter, compared to analyst estimates of $30.09 million. On average, sell-side analysts anticipate that Agenus will post -12.55 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Agenus
Agenus Company Profile
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Read More
- Five stocks we like better than Agenus
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- 3 Undervalued Stocks You Can Buy at a Discount Now
- How to Calculate Inflation Rate
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- Top Stocks Investing in 5G Technology
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.
